ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.84 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-05-07
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.84, a 8.78% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.53, a 2.92% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.43, a 36.65% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.51, a 68.74% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.56, a 3.79% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.43, a 36.65% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.51, a 68.74% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.03, a 40.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-03-31 | $3.84 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.56 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $3.53 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $3.53 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $3.53 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $3.43 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $3.43 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $3.43 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $3.43 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.51 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $2.51 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $2.51 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $2.51 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $8.03 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $8.03 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $8.03 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $8.03 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $13.57 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $13.57 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $13.54 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $13.54 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $4.04 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $4.04 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $4.04 10-Q · filed 2020-08-10 | |||
| 2019-12-31 | $7.08 10-K · filed 2020-03-09 | |||
| 2019-09-30 | $7.08 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $7.08 10-Q · filed 2019-08-09 | |||
| 2018-12-31 | $5.99 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |